Combo Disappoints in Metastatic Prostate Cancer Combo Disappoints in Metastatic Prostate Cancer

Combining the tyrosine kinase inhibitor saracatinib with docetaxel does not benefit patients with metastatic, castration-resistant prostate cancer, according to researchers.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news